comparemela.com
  1. Home
  2. Live Updates
  3. Karim Dabbagh - Breaking News

Page 2 - Karim Dabbagh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

/PRNewswire/ Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers,.

Susannah cantrellKarim dabbaghArena pharmaceuticalsGilead sciences incSecond genomeChief executive officerChief operating officerChief business officerGilead sciences

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

/PRNewswire/ Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers,.

Joseph dal portoKarim dabbaghColitis organizationArena pharmaceuticalsDrug administrationGilead sciences incEuropean crohnChief executive officerSecond genomeChief science officerVirtual plenary hallMucosal healingGilead sciencesHealth care amp hospitalsMedical pharmaceuticalsOlls and research

Second Genome Appoints Joseph Dal Porto, Ph D , as Chief Scientific Officer

/PRNewswire/ Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers from.

United statesDal portoJoseph dal portoKarim dabbaghJohns hopkins universityArena pharmaceuticalsNational jewish medical research centerUniversity of maryland school medicinePreclinical researchGilead sciences incChief scientificChief executive officerSecond genomeVice presidentEmerging scienceSite head

Second Genome Appoints Joseph Dal Porto, Ph D , as Chief Scientific Officer

/PRNewswire/ Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers from.

United statesDal portoJoseph dal portoKarim dabbaghJohns hopkins universityArena pharmaceuticalsNational jewish medical research centerUniversity of maryland school medicinePreclinical researchGilead sciences incChief scientificChief executive officerSecond genomeVice presidentEmerging scienceSite head

Second Genome Appoints Joseph Dal Porto, Ph D , as Chief Scientific Officer

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer - read this article along with other careers information, tips and advice on BioSpace

United statesDal portoJoseph dal portoKarim dabbaghJohns hopkins universityArena pharmaceuticalsNational jewish medical research centerUniversity of maryland school medicinePreclinical researchGilead sciences incChief scientificChief executive officerSecond genomeVice presidentEmerging scienceSite head

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.